Breakdown of the EFPIA contribution as of the end of 2016

**IMI1 in-kind contribution by company**

- AstraZeneca AB, 11.54%
- Sanofi Aventis, 11.32%
- Glaxosmithkline, 8.75%
- Bayer Pharma, 6.64%
- Novartis, 6.24%
- Merck KGaA, 5.14%
- Boehringer Ingelheim, 5.40%
- F. Hoffman-La Roche, 6.17%
- Pfizer, 4.99%
- H. Lundbeck, 3.05%
- UCB Pharma, 3.06%
- Eli Lilly, 2.93%
- Abbvie, 2.14%
- Others, 8.36%
- Janssen, 11.91%

Companies listed under 'Other' are: Abbott, AlCURIS Anti-Infective Cures GmbH, Almirall, Amgen, Astellas Pharma Europe, Basilea, Biogen Idec, Bristol Myers Squibb, Chiesi Farmaceutici, Eisai, Farmaindustria, Grünenthal, INFARMA, Ipsen, Laboratorios del Dr Esteve, Menarini, Merck Sharp & Dohme, Novo Nordisk, Orion Corporation, Sanofi-Aventis Groupe, Sigma-Tau, Takeda, VFA, Vifor

**IMI1 in-kind contribution by category**

- Personnel costs, 55.69%
- Subcontracting, 17.46%
- Financial contribution, 6.84%
- Other direct costs, 20.03%
IMI2 in-kind contribution by organisation

Organisations included under 'Other' are: AbbVie, Actelion Pharmaceuticals, Arrgen, Bayer Pharma, Biogen Idec Limited, Boehringer Ingelheim, Bristol-Myers Squibb Company, EFPIA, F. Hoffmann-La Roche, GE Healthcare, Grünenthal, H. Lundbeck, Institute de Recherche Servier, Intervet International, IPSEN Innovation, JDRF International, Merck, MSD IT Global Innovation Center, Novartis Pharma, Novo Nordisk, Pfizer Limited, Piramal Imaging, Takeda Development Centre Europe Ltd., The Leona M. and Harry B. Helmsley Charitable Trust, UCB Biopharma.

EFPIA in-kind contribution to IMI2 by category

- Indirect costs: 46.6%
- Personnel costs: 29.9%
- Financial contribution: 15.8%
- Subcontracting: 32.5%
- Other direct costs: 2.9%